?Sorafenib Tosylate | Anticancer Tyrosine Kinase Inhibitor, 99% Purity, USP/EP Certified?

? ?Product Overview?

Sorafenib Tosylate is a ?multitarget tyrosine kinase inhibitor? approved for advanced ?hepatocellular carcinoma (HCC)?, ?renal cell carcinoma (RCC)?, and ?thyroid cancer?. It inhibits ?VEGFR, PDGFR, and RAF kinases?, blocking tumor angiogenesis and proliferation. As the active ingredient in Nexavar?, it is widely used in ?first-line therapy? for unresectable liver and kidney cancers.

? ?Key Advantages?

?? ?High Potency & Selectivity?

• Targets ?VEGFR-2 (IC??: 90 nM)? and ?RAF-1 (IC??: 6 nM)? with precision?45.

• ?>99% purity? (HPLC/UV validated) for pharmaceutical-grade quality?26.

?? ?Broad-Spectrum Antitumor Activity?

• Dual action: suppresses tumor growth ?and? angiogenesis?45.

• Effective against ?BRAF-mutated cancers? (e.g., melanoma)?4.

?? ?Oral Bioavailability?

• Single-dose convenience with ?prolonged therapeutic effects??5.

? ?Applications?

• ?Hepatocellular Carcinoma (HCC)?: First-line treatment for advanced stages?13.

• ?Renal Cell Carcinoma (RCC)?: Standard therapy for metastatic cases?13.

• ?Thyroid Cancer?: Approved for radioactive iodine-resistant tumors?35.

• ?Clinical Research?: Investigated for NSCLC and melanoma?45.

? ?Quality Certifications?

• Complies with ?USP/EP/BP monographs??23.

• Batch-specific ?COA? with ?HPLC, NMR, and residual solvent analysis??67.

• Stability tested under ?ICH Q1A guidelines? (24-month shelf life)?67.

? ?Market Trends?

The global oncology kinase inhibitor market is projected to grow at ?CAGR 8.5% (2025–2030)?, driven by rising HCC/RCC prevalence?35. Sorafenib Tosylate remains a cornerstone therapy, with ?$1.2 billion annual sales? in 2024, supported by its proven efficacy and expanding off-label applications?35.